Supriya Lifescience Ltd
As of 20 Nov 2026, Supriya Lifescience is in Stage 3, the topping phase, now in week 2 (since 12 Nov 2026). It closed at ₹620, 41.1% below its 52-week high and below its 200-day average, which is rising. In Health Care, 34.7% of stocks are in Stage 2.
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. More about the company
Pro read
ProSUPRIYA's uptrend is tiring: 2 weeks into a top. A topping stock either breaks back out or rolls over into a decline, and the next few weeks usually settle which.
Its relative strength is 39 of 99, below the middle among NSE stocks over the past year. Pharmaceuticals ranks 7 of 106 industries by the strength of its stocks, among the leaders.
Is SUPRIYA early, or has it already run? Pro answers that for every NSE stock, after every close.
SUPRIYA among Pharmaceuticals90th of 118 by relative strength
All 118 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | BLISSGVS | Stage 2 · wk 49 | 99 | +4.6% |
| 2 | KPL | Stage 2 · wk 44 | 99 | +20.5% |
| 3 | FREDUN | Stage 2 · wk 33 | 98 | +24.0% |
| 4 | VENUSREM | Stage 3 · wk 10 | 98 | −1.5% |
| 5 | RUBICON | Stage 3 · wk 4 | 98 | +18.7% |
| 6 | SAKAR | Stage 2 · wk 55 | 98 | +13.1% |
| 7 | BAFNAPH | Stage 2 · wk 23 | 98 | +1.9% |
| 8 | INDSWFTLAB | Stage 2 · wk 23 | 98 | −7.4% |
| …90 | SUPRIYA | Stage 3 · wk 2 | 39 | −26.4% |
Mutual fund holdings
Held by 10 mutual funds in portfolios to October 2026: 3 active funds and 7 index funds and ETFs.
In October, no active fund changed its holding.
All 10 funds and what each did in October
Mutual funds holding SUPRIYA: the ten largest and the month’s moves →
Supriya Lifescience: quick answers
What stage is Supriya Lifescience in?
As of 20 Nov 2026, Supriya Lifescience (SUPRIYA) is in Stage 3, the topping phase. It entered Stage 3 on 12 Nov 2026 and is in week 2. What the four stages mean
Is Supriya Lifescience in an uptrend?
Its uptrend has stalled. Supriya Lifescience is in Stage 3, the topping phase that follows an advance. It trades 20.8% below its 200-day average, which is rising.
How far is Supriya Lifescience from its 52-week high?
Supriya Lifescience closed at ₹620 on 20 Nov 2026, 41.1% below its 52-week high of ₹1,053. Its 52-week low is ₹553.
How has Supriya Lifescience performed over the past year?
As of 20 Nov 2026, Supriya Lifescience is down 21.2% over the past year and down 17.5% so far in 2026.
Which sector and industry is Supriya Lifescience in?
Supriya Lifescience is in the Pharmaceuticals industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Pharmaceuticals
About this companyHealth Care· Pharmaceuticals
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, antihypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.
Visit company website →All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.